MELT-300, a combination of midazolam and ketamine administered sublingually before cataract surgery, achieved the primary sedation endpoint in a pivotal phase 2 efficacy and safety study, Melt Pharmaceuticals announced in a press release.
The trial evaluated MELT-300 against placebo, as well as midazolam alone and ketamine alone. The primary efficacy endpoints were appropriate cataract surgery sedation and management of intraoperative pain during cataract surgery.
MELT-300 was superior to all comparator arms for procedural sedation. In addition, participants who received MELT-300 were 50% less